AGENDA

El epigenoma de la leucemia: implicaciones biológicas y clínicas

El jueves 14 de julio el ISPA acogió la Conferencia El epigenoma de la leucemia: implicaciones biológicas y clínicas, del investigador José Ignacio Martín Subero, responsable del grupo de Epigenómica biomédica de IDIBAPS. La charla formó parte del ciclo de conferencias sobre cáncer patrocinado por Janssen y tuvo lugar a las 13:00 h en la sala N-1 S2 006 del HUCA.

Presentación José Ignacio Martín Subero

Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University of Kiel (Germany). He continued his postdoctoral training at the Christian-Albrechts University and in 2005 he became faculty member. Upon returning to Spain in 2009, worked at the IDIBELL of Barcelona and in 2010 he started to coordinate a research group on epigenomics at the University of Barcelona. In 2016, he was appointed leader of the Biomedical Epigenomics group at the IDIBAPS research institute in Barcelona, and in 2018 we was awarded with an ICREA Research Professorship. He has published over 200 peer-reviewed articles. His research is focused on the application of advanced sequencing and computational technologies to characterize epigenomic marks in normal and neoplastic lymphoid cells. His ultimate goal is that the generated epigenomic knowledge can be translated into a benefit for patients with lymphoid neoplasms, in terms of better diagnosis, estimation of prognosis and more appropriate treatments.

Temática de la charla

During the talk, Dr. Martin-Subero will summarize the main findings of his research on the epigenome of the most common form of leukemia, chronic lymphocytic leukemia (CLL). He will present a variety of epigenomic studies, including the analysis of DNA methylation, histone modifications, chromatin accessibility and the 3D genome structure of CLL. These studies have led to the following major biological and clinical insights:

  • Identification of three CLL subgroups based on DNA methylation imprints of B cells at different maturation stages. These three subgroups are strongly associated with the clinical behavior of the patients (Article 1)
  • Development of a mitotic clock to estimate the past proliferative history of CLL cells and estimate the future clinical behavior of patients (Article 3).
  • A multi-omic analysis of 9 epigenetic layers reveals a widespread de novo activation of chromatin in CLL, which seems to be mediated by the action of few TFs (Article 2).
  • Characterization of the genome-wide 3D genome structure in CLL as compared to normal B cell subpopulations. This study has revealed the presence of large blocks of the CLL genome that change their 3D structure and contain genes involved in CLL pathogenesis (Article 4).

 

    1. Kulis et al. Nat Genet. 2012 Nov;44(11):1236-42.
    2. Beekman et al. Nat Med. 2018 Jun;24(6):868-880.
    3. Duran-Ferrer et al., Nat Cancer. 2020 Nov;1(11):1066-1081.
    4. Vilarrasa-Blasi & Soler-Vila et al. Nat Commun. 2021 Jan 28;12(1):651.